Cargando…

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy

BACKGROUND: Resistance to BRAF inhibitors is an emerging problem in the melanoma field. Strategies to prevent and overcome resistance are urgently required. METHODS: The dynamics of cell signalling, BrdU incorporation and cell-cycle entry after BRAF inhibition was measured using flow cytometry and w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paraiso, K H T, Fedorenko, I V, Cantini, L P, Munko, A C, Hall, M, Sondak, V K, Messina, J L, Flaherty, K T, Smalley, K S M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883709/ https://www.ncbi.nlm.nih.gov/pubmed/20531415 http://dx.doi.org/10.1038/sj.bjc.6605714

Ejemplares similares

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels
por: Smalley, K S M, et al.
Publicado: (2007)

Beyond BRAF: where next for melanoma therapy?
por: Fedorenko, I V, et al.
Publicado: (2015)

BRAF inhibition generates a host/tumor niche that mediates therapeutic escape
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
por: Carlino, M S, et al.
Publicado: (2014)

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
por: Nakayama, N, et al.
Publicado: (2008)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

Role of MEK/ERK pathway in the MAD2-mediated cisplatin sensitivity in testicular germ cell tumour cells
por: Fung, M K L, et al.
Publicado: (2006)

Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients
por: Zlobec, I, et al.
Publicado: (2010)

Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation
por: Minas, V, et al.
Publicado: (2007)

The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting
por: Kailayangiri, S, et al.
Publicado: (2012)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
por: Oddo, Daniele, et al.
Publicado: (2017)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy
por: Sathe, A, et al.
Publicado: (2014)

Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma
por: Oguejiofor, K, et al.
Publicado: (2015)

MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours
por: Khandelwal, A, et al.
Publicado: (2008)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

CD44 targets Na(+)/H(+) exchanger 1 to mediate MDA-MB-231 cells' metastasis via the regulation of ERK1/2
por: Chang, G, et al.
Publicado: (2014)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
por: Hassel, J C, et al.
Publicado: (2010)

Generation of tumour-specific cytotoxic T-cell clones from histocompatibility leucocyte antigen-identical siblings of patients with melanoma
por: Gottlieb, D J, et al.
Publicado: (2006)

Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA
por: Henare, K, et al.
Publicado: (2012)

Resistance of uveal melanoma to the interstrand cross-linking agent mitomycin C is associated with reduced expression of CYP450R
por: Gravells, P, et al.
Publicado: (2011)

Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes
por: Calcagno, A M, et al.
Publicado: (2008)

Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells
por: Timoshenko, A V, et al.
Publicado: (2007)

Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response
por: Ivarsson, K, et al.
Publicado: (2005)

Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer
por: Cheng, Y Y, et al.
Publicado: (2007)

Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression
por: Yamana, K, et al.
Publicado: (2005)

Expression and DNA methylation of TNF, IFNG and FOXP3 in colorectal cancer and their prognostic significance
por: Ganapathi, S K, et al.
Publicado: (2014)

Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signalling and cell-cycle regression in ovarian cancer cells
por: Singh, R K, et al.
Publicado: (2008)

Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines
por: Mohammed, M Z, et al.
Publicado: (2011)

Phellinus linteus suppresses growth, angiogenesis and invasive behaviour of breast cancer cells through the inhibition of AKT signalling
por: Sliva, D, et al.
Publicado: (2008)

In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol
por: Chander, S K, et al.
Publicado: (2007)

Temozolomide induces senescence but not apoptosis in human melanoma cells
por: Mhaidat, N M, et al.
Publicado: (2007)

Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence
por: Pandya, K, et al.
Publicado: (2011)

Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy
por: Fareed, K R, et al.
Publicado: (2010)

Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice
por: Huynh, C K, et al.
Publicado: (2006)

COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer
por: Timoshenko, A V, et al.
Publicado: (2006)

Colocalisation of CD9 and mortalin in CD9-induced mitotic catastrophe in human prostate cancer cells
por: Zvereff, V, et al.
Publicado: (2007)

Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
por: Tijono, S M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_tuhn8hl5jq6j911aiq4a0qbina